American Oncology Network to Present 10+ Studies at ASCO 2026, Highlighting AI and Health Equity
Event summary
- American Oncology Network (AON) will present 10+ studies at ASCO 2026, covering AI, health equity, and novel therapies.
- Studies include Phase 3 trial data for ZL-1310 in small cell lung cancer and AI-powered clinical trial platforms.
- AON physicians contributed research on health disparities, machine learning projections, and LLMs in patient guidance.
- Network spans 350+ providers across 21 states, with 150+ active clinical trials.
- ASCO 2026 runs May 29–June 2 in Chicago, featuring 145+ hours of oncology education.
The big picture
AON's ASCO presence underscores the growing role of community oncology networks in advancing cancer research. The focus on AI and health equity aligns with broader industry shifts toward data-driven, patient-centric care models. With 150+ active trials, AON is positioning itself as a key player in decentralizing oncology innovation beyond academic centers.
What we're watching
- AI Integration
- How AON's AI-powered registry platform will scale real-world evidence collection across its network.
- Therapeutic Breakthroughs
- Whether ZL-1310's Phase 3 data positions it as a competitive option for relapsed small cell lung cancer.
- Health Equity Impact
- The pace at which AON's disparities research translates into actionable policy changes in community oncology.
Related topics